Use of tumor necrosis factor inhibitors to treat cardiovascular disease

A method of identifying a chronic heart failure patient who qualifies to receive treatment with a TNFα inhibitor, said method comprising:

• measuring in the patient's serum the level of a marker comprising at least one substance selected from the group consisting of TNFA;
• an interleukin associated with inflammation, including IL-1, IL-1 beta, IL-1 alpha, IL6, IL8, IL18;
• MMPs;
• TNF receptors (type I or II);
• serum creatinine;
• high sensitivity C-reactive protein (CRP) levels;
• troponin;
• BNP;
• cerimide;
• a chemokine;
• MCP-1;
• lymphotoxin α;
• an endothelin;
• an endothelin receptor;
• big endothelin;
• endothelin-2;
• endothelin receptor type A;
• endothelin receptor type B;
• an indicator of the andrenergic system;
• norepinephrine;
• epinephrine;
• an alpha andrenergic receptor;
• beta 1 andrenergic receptor;
• beta 2 andrenergic receptor;
• beta 3 andrenergic receptor;
• an indicator of the renin-angiotensin system;
• renin;
• angiotensin;
• aldosterone;
• an angiotensin converting enzymes;
• a natriuretic peptide family member;
• BNP;
• ANP;
• CNP;
• an acute phase protein;
• CRP;
• PIIINP;
• a nitric oxide synthase;
• INOS;
• an epithelial growth factor receptor;
• an epithelial growth factor ligands;
• and
• determining that the patient's serum level of said substance is at least two times higher than the level of the same substance in the serum of a patient who does not have chronic heart failure.